menu
    • menu
    [{"orgOrder":0,"company":"Microbio","sponsor":"Microbio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Immunology","graph2":"Undisclosed","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Microbio \/ Microbio","highestDevelopmentStatusID":"1","companyTruncated":"Microbio \/ Microbio"},{"orgOrder":0,"company":"Microbio","sponsor":"Microbio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Oncology","graph2":"Undisclosed","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbio \/ Microbio","highestDevelopmentStatusID":"1","companyTruncated":"Microbio \/ Microbio"},{"orgOrder":0,"company":"Microbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MS-20","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase I","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Microbio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Microbio \/ Undisclosed"},{"orgOrder":0,"company":"Microbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Microbio \/ Undisclosed"},{"orgOrder":0,"company":"Microbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Oncology","graph2":"Undisclosed","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Microbio \/ Undisclosed"},{"orgOrder":0,"company":"Microbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"MB-110","moa":"Hepatitis C virus Non-structural 5A (HCV NS5A)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Microbio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Microbio \/ Undisclosed"},{"orgOrder":0,"company":"Microbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"MB-6","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Microbio \/ Undisclosed"},{"orgOrder":0,"company":"Microbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"TAIWAN","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"MBS","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Microbio \/ Undisclosed"},{"orgOrder":0,"company":"Microbio","sponsor":"Oneness Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SNS812","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Microbio \/ Microbio","highestDevelopmentStatusID":"8","companyTruncated":"Microbio \/ Microbio"}]

    Find Clinical Drug Pipeline Developments & Deals by Microbio

    Menu

    Microbio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MS-20,Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Microbio's "MS-20" Shows Promise as Add-On Therapy for Ulcerative Colitis

                            Details : MS-20 is a postbiotic produced through the symbiotic fermentation of multi-strain probiotics. It is being investigated for immunological and gastrointestinal diseases.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : MS-20,Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNS812

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Oneness Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pan-COVID New Drug - SNS812 Achieves Superiority in Phase 2 Study

                            Details : SNS812 achieves statistical significance with clinically meaningful endpoints in the Phase 2 trial and is the only therapeutic with a broad-spectrum efficacy in multiple coronavirus variants.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 10, 2024

                            Lead Product(s) : SNS812

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Oneness Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MS-20

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Recipient : National Taiwan University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MS-20 on Patients With Ulcerative Colitis(UC)

                            Details : MS-20 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            June 01, 2021

                            Lead Product(s) : MS-20

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Recipient : National Taiwan University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MS-20

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination w...

                            Details : MS-20 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            June 01, 2021

                            Lead Product(s) : MS-20

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MS-20

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals

                            Details : MS-20 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            December 19, 2020

                            Lead Product(s) : MS-20

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBS

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Postbiotic MBS and Metformin Combination in Patients With T2DM

                            Details : MBS is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            November 20, 2020

                            Lead Product(s) : MBS

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MS-20

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : National Taiwan University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MS-20 on Gut Microbiota and Risk/Severity of Cachexia in Pancreatic Cancer Patients

                            Details : MS-20 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            October 23, 2020

                            Lead Product(s) : MS-20

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : National Taiwan University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MB-110

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Pa...

                            Details : MB-110 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis C, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 01, 2015

                            Lead Product(s) : MB-110

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            Microbio

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MB-6

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675)

                            Details : MB-6 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 13, 2010

                            Lead Product(s) : MB-6

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth